LON:IMM ImmuPharma (IMM) Share Price, News & Analysis → Buy Friday, Sell Monday, No Exceptions (From DTI) (Ad) Free IMM Stock Alerts GBX 2.17 -0.01 (-0.46%) (As of 03:03 PM ET) Add Compare Share Share Today's Range 2.11▼ 2.3750-Day Range 0.85▼ 2.5052-Week Range 0.82▼ 3.80Volume1.72 million shsAverage Volume2.68 million shsMarket Capitalization£9.04 millionP/E RatioN/ADividend Yield0.77%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get ImmuPharma alerts: Email Address Ad MarketBeatYour $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionStart Your Risk-Free Trial Here About ImmuPharma Stock (LON:IMM)ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.Read More IMM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMM Stock News HeadlinesMarch 25, 2024 | lse.co.ukIncanthera says first order from skincare deal doublesMarch 15, 2024 | msn.comSMALL CAP MOVERS: Versarien soars as advanced materials group offloads non-core assetsMarch 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.March 8, 2024 | finance.yahoo.comImmuPharma CEO Tim McCarthy discusses financial stability and promising drug developmentsFebruary 24, 2024 | morningstar.comImmuPharma PLC IMMFebruary 21, 2024 | lse.co.ukUK government borrowing surplus rises in January from prior yearJanuary 17, 2024 | ca.finance.yahoo.comImmuPharma PLC (25I.SG)December 19, 2023 | lse.co.ukEARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrowsMarch 28, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. August 31, 2023 | lse.co.ukImmuPharma launches GBP2 million fund raise as interim loss narrowsAugust 31, 2023 | marketwatch.comImmuPharma to Raise up to GBP1.85 Mln to Fund R&D Pipeline, Working CapitalAugust 21, 2023 | lse.co.ukImmuPharma agrees 12 month extension to Incanthera warrant instrumentJune 27, 2023 | proactiveinvestors.comImmuPharma "absolutely delighted" to push on with new clinical trialJune 19, 2023 | proactiveinvestors.comImmuPharma presses on with next phase of Lupuzor clinical trialsMay 24, 2023 | proactiveinvestors.comImmuPharma "looking forward with quiet confidence" to FDA responseMay 18, 2023 | uk.investing.comFTSE 100 remains higher but off best with Wall Street indicated mixedMay 18, 2023 | marketwatch.comImmuPharma Shares Rise on Positive Guidance From US FDA for P140May 18, 2023 | proactiveinvestors.comImmuPharma shares jump 6.5% after FDA updateMay 18, 2023 | proactiveinvestors.comImmuPharma says CIDP trial will begin in the second half after meeting with US regulatorMay 12, 2023 | marketwatch.comSystemic Lupus Erythematous SLE Drug Market, Global Outlook and Forecast 2023-2029May 11, 2023 | proactiveinvestors.comImmuPharama eyes clinical trial progressMay 11, 2023 | proactiveinvestors.comImmuPharma eyes clinical trial progressApril 27, 2023 | proactiveinvestors.comImmuPharma "looking forward" to upcoming FDA meetingsApril 19, 2023 | proactiveinvestors.comImmuPharma partner gets FDA meeting dateApril 12, 2023 | marketwatch.comImmuPharma Shares Jump as FDA Meeting Date Set for P140 Clinical ProgramApril 12, 2023 | proactiveinvestors.comImmuPharma rises 4% after it reveals headway with lead assetApril 12, 2023 | proactiveinvestors.comImmuPharma makes progress developing second indication for lead assetSee More Headlines Receive IMM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmuPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/30/2020Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:IMM CUSIPN/A CIKN/A Webwww.immupharma.org Phone+44-20-71524080FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-2,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-159.35% Return on Assets-53.90% Debt Debt-to-Equity RatioN/A Current Ratio1.17 Quick Ratio1.03 Sales & Book Value Annual Sales£94,819.00 Price / Sales95.74 Cash FlowGBX 0.11 per share Price / Cash Flow20.50 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares416,440,000Free FloatN/AMarket Cap£9.08 million OptionableNot Optionable Beta1.32 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Timothy Paul McCarthy XIV (Age 68)FCCA, M.B.A., MBA, Chairman & CEO Comp: $106.5kDr. Timothy Gary Franklin M.B.A. (Age 60)Ph.D., COO & Director Comp: $92.5kMs. Lisa Baderoon (Age 58)Head of Investor Relations & Non Executive Director Comp: $48kDr. Jean-Marie Geiger PharmDMD, Head of Clinical DevelopmentDr. Laura Mauran-AmbrosinoChief Scientific Officer of ImmuPharma BiotechMs. Lara E. Sucheston-CampbellHead of Clinical & Medical AffairsDr. Sébastien R. Goudreau Ph.D. (Age 43)CEO of ImmuPharma Biotec & Director More ExecutivesKey CompetitorsSynairgenLON:SNGSareumLON:SARBiVictriX TherapeuticsLON:BVXRoquefort TherapeuticsLON:ROQRealm TherapeuticsLON:RLMView All Competitors IMM Stock Analysis - Frequently Asked Questions How have IMM shares performed in 2024? ImmuPharma's stock was trading at GBX 1.67 at the beginning of 2024. Since then, IMM stock has increased by 39.1% and is now trading at GBX 2.32. View the best growth stocks for 2024 here. How were ImmuPharma's earnings last quarter? ImmuPharma plc (LON:IMM) announced its quarterly earnings data on Wednesday, September, 30th. The company reported ($1.69) EPS for the quarter. What other stocks do shareholders of ImmuPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuPharma investors own include Castleton Technology (CTP), MOTIF BIO PLC/S (MTFB), Aminex (AEX), Legendary Investments (LEG), Richland Resources Ltd (RLD.L) (RLD), Sound Energy (SOU), Thor Energy (THR), Acacia Mining (ACA), ALU (ALU) and (DARA) (DARA). How do I buy shares of ImmuPharma? Shares of IMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:IMM) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuPharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.